

NIH funding opportunities

05 December 2024 (#31)



Confirm your intent to apply *ASAP*, but not later than *60 days* before the submission date.



See all Important Notices, Parent Announcements and Notice of Special Interest below

Plan your application. Before starting your application attend

- 1) *Generic Grant Writing Workshop and then the*
- 2) *NIH Grant Writing Workshop*

To prepare an application can take *4-18 months*.

From submission to receiving a Notice of Award can take *10 months*

Important Notices

[NOT-HS-25-006](#) New "FORMS-I" Grant Application Forms and Instructions Coming for Due Dates on or after January 25, 2025. The following application forms include substantive form changes (i.e., new/deleted/modified fields). All other forms include only an OMB expiration date change.

- PHS 398 Research Training Program Plan
- PHS Fellowship Supplemental Form
- PHS Assignment Request Form
- PHS 398 Cover Page Supplement Form

Application guides for FORMS-I application packages will be posted to the [How to Apply - Application Guide](#) page in November 2024.

[NOT-AI-25-007](#) Request for Information (RFI): Researching COVID to Enhance Recovery – Treating Long COVID (RECOVER-TLC). Today, there are no approved therapies to treat Long COVID or its symptoms, leaving millions of patients suffering and waiting for answers. Trying to counter this public health crisis, the NIH announced the next phase of its Long COVID research program: Researching COVID to Enhance Recovery–Treating Long COVID (RECOVER-TLC) led by National Institute of Allergy and Infectious Disease (NIAID), in collaboration with National Heart, Lung, and Blood Institute (NHLBI) and the National Institute of Neurological Disorders and Stroke (NINDS). The goal of this initiative is to work rapidly, collaboratively, and transparently to advance treatments for Long COVID. RECOVER-TLC will apply lessons learned from the ongoing program, RECOVER, launched in 2021. Responses may be submitted up until 12:00 AM EST February 1, 2025. Please direct all inquiries to: recover-tlc-submissions@nih.gov

[NOT-HG-25-011](#) Notice of Intent to Publish a Funding Opportunity Announcement for Supporting Talented Early Career Researchers in Genomics (R01 Clinical Trial Optional). The purpose of this Notice is to inform the research community that the National Human Genome Research Institute (NHGRI) intends to publish a renewal of RFA-HG-22-001: Supporting Talented Early Career Researchers in Genomics. This Notice is being provided to allow potential applicants sufficient time to develop responsive projects. Expected Number of Awards: 3-5 per year. Estimated Award

Ceiling: Application budgets are limited to less than \$400,000 in direct costs per year and must reflect the actual needs of the proposed project. First Estimated Application Due Date: February 28, 2025.

Parent Announcements

[NOT-OD-24-099](#) Notice to Extend Parent R01/R03/R21 Parent Notices of Funding Opportunities. Current Key Dates **Modified Expiration Date: January 8, 2025**

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Notice of Special Interest (NOSI)

[NOT-AI-24-085](#) Somatic Cell Gene Editing Therapies to Improve Transplantation Outcomes. The National Institute of Allergy and Infectious Diseases (NIAID) is interested in supporting research that applies somatic cell gene editing (SCGE) approaches in animal models or human tissues or organs excluded from clinical use to improve graft survival and outcomes for recipients of allogeneic or xenogeneic solid organ or pancreatic islet transplants, or vascularized composite allografts (VCA). This notice applies to due dates on or after February 5, 2025 and subsequent receipt dates through November 16, 2027.

[NOT-CA-25-012](#) Dissemination and Implementation Science for Cancer Prevention and Control in Low Resource Environments. The purpose of this notice of special interest (NOSI) is to inform potential applicants of the interest of the National Cancer Institute (NCI) in supporting implementation research related to cancer prevention and control in low- and middle-income countries (LMICs). For the purposes of this NOSI, LMICs are defined according to the [World Bank Country and Lending Groups](#) and are inclusive of low-income, lower-income, and upper-middle income economies. This Notice applies to application due dates on or after October 5, 2024, and subsequent receipt dates through January 7, 2028. This NOSI expires on January 08, 2028.

[NOT-CA-25-003](#) Implementation Science for Climate Change and Health. The purpose of this Notice is to inform potential applicants of the interest of the NIH Climate Change and Health Initiative (CCHI) in supporting implementation science related to climate change and health. The CCHI seeks to reduce the health threats posed by climate change across the lifespan, improve the health of people who are at increased risk from or disproportionately impacted by climate change, and build health resilience among individuals, organizations, communities, Tribal Nations, and nations around the world. This NOSI encourages applications that propose implementation studies to understand and address barriers and facilitators to the adoption, implementation, scale-up, and sustainment of effective interventions to prevent or mitigate the health effects of climate change in the United States and globally. This Notice applies to application due dates on or after February 5, 2025, and subsequent receipt dates through January 7, 2028.

[NOT-AI-24-082](#) Establishing and Utilizing Pre-Clinical Animal Models to Study Post-TB Lung Disease Development. The purpose of this NOSI is to invite applications for basic and translational research establishing and utilizing animals to model the development of post-TB lung disease (PTLD). This NOSI will support the establishment and utilization of pre-clinical animal models that strive to (1) better understand the pathophysiology of long-term lung damage resulting from pulmonary TB or (2) better understand the role of the immune response during TB treatment in long-term lung

damage. Validating results with animal models using clinical samples is allowable, but clinical trials and clinical research will not be supported under this NOSI. This notice applies to due dates on or after February 5, 2025 and subsequent receipt dates through January 7, 2028.

Notice of Funding Opportunity (NOFO)

[RFA-AI-24-023 U.S.-South Africa Program for Collaborative Biomedical Research – Phase 3 \(HIV/AIDS\) \(R01 Clinical Trial Optional\)](#). The purpose of this Notice of Funding Opportunity (NOFO) is to support research projects under Phase 3 of the U.S.-South Africa Program for Collaborative Biomedical Research. Research areas supported under this program include HIV/AIDS, HIV/AIDS co-morbidities and co-infections, HIV/AIDS-associated implementation science, and HIV/AIDS-associated data science. The hallmark of the U.S.-South Africa program is the development of collaborative partnerships between South African investigators and United States (U.S.) investigators. Through international collaboration, this research will advance scientific discoveries, promote sharing of technologies and approaches, and serve local public health needs and priorities in support of global HIV/AIDS research.

AIDS Date: March 12, 2025. All applications are due by 5:00 PM local time of applicant organization. **Letter of Intent:** 30 days prior to the application due date.

Budget: Issuing IC and partner components intend to commit an estimated total of \$3.8 million to fund 8-10 awards. Application budgets are not expected to exceed \$400,000 in direct costs per year and should reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Important Notice: All potential applicants **MUST** inform the Grants Management Office **before** 12 January 2025 of their intention to apply. This must include the specific aims, participating institutions and list of all key personnel and consultants. Only after receiving this internal letter of intent, meetings with the PI will be scheduled and project plans will be prepared. **Please also contact the Scientific Program officials** listed in the NOFO to ensure that your application is responsive to the call.

[PAR-25-300 Targeting Cell Surface HIV Envelope for Cell Elimination \(R01 Clinical Trial Not Allowed\)](#). The purpose of this notice of funding opportunity (NOFO) is to support the investigation of HIV-1 Envelope (Env) cell surface expression, the structural mechanism of biologic-mediated cell killing, and the development of novel approaches to enhance the recognition and elimination of Env-expressing, HIV-1 infected cells. These studies are expected to inform the development of immunotherapies and targeted vaccines for HIV-1 prevention and cure.

Date: May 07, 2025 through to January 07, 2028. All applications are due by 5:00 PM local time of applicant organization.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is five years. Applicants requesting \$500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific Contact at least 8 weeks before submitting the application.

[PAR-25-053 Translational Neural Devices \(R61/R33 - Clinical Trial Optional\)](#). The purpose of this Notice of Funding Opportunity (NOFO) is to encourage investigators to pursue translational activities and small clinical studies to advance the development of low risk therapeutic and diagnostic devices for disorders that affect the nervous or neuromuscular systems. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, obtaining Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study (R61 phase), as well as a subsequent small clinical study (R33 phase). The clinical study is expected to provide information about the device function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This NOFO utilizes an Exploratory/Developmental Phased Award and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress. Transition from the R61 to the R33 phase is contingent upon the successful completion of proposed milestones.

Date: January 28, 2025 through to January 28, 2027. All applications are due by 5:00 PM local time of applicant organization.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. In all cases, applicants should propose a budget that is reasonable and appropriate for completion of the research project. The proposed project period for the R61 phase must not exceed 2 years. The proposed project period for the R33 phase must not exceed 4 years. The total duration of the R61 and R33 may not exceed 5 years. Applicants requesting \$500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific Contact at least 8 weeks before submitting the application.

[PAR-25-144](#) Dissemination and Implementation Research in Health (R01 Clinical Trial Optional). The purpose of this Notice of Funding Opportunity (NOFO) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, sustainability, scale-up, and spread of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies (hereafter referred to as evidence-based interventions). Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (de-implement) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. Applications that focus on re-implementation of evidence-based health services that may be disrupted amidst disasters (e.g., pandemics, climate change) remain relevant. **All applications must be within the scope of the mission of one of the Institutes/Centers listed.**

Date: February 05, 2025 through to January 07, 2028. All applications are due by 5:00 PM local time of applicant organization.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years. Applicants requesting \$500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific Contact at least 8 weeks before submitting the application.

[PAR-25-233](#) Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed). The purpose of this Notice of Funding Opportunity (NOFO) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, sustainability, scale-up, and spread of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies (herein referred to collectively as evidence-based interventions). Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (de-implement) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. Applications that focus on re-implementation of evidence-based health services that may be disrupted amidst disasters (e.g., pandemics, climate change) remain relevant. All applications must be within the scope of the mission of one of the Institutes/Centers listed.

Date: February 16, 2025 through to January 07, 2028. All applications are due by 5:00 PM local time of applicant organization.

Budget: A budget for direct costs of up to \$50,000 per year may be requested. The maximum project period is 2 years.

[PAR-25-185](#) Screening and Functional Validation of Genomic Variants Associated with Human Congenital Anomalies (R01 Clinical Trial Not Allowed). To conduct and support laboratory research, clinical trials, and studies with people that explore health processes. NICHD researchers examine growth and development, biologic and reproductive functions, behavior patterns, and population dynamics to protect and maintain the health of all people. To examine the impact of disabilities, diseases, and defects on the lives of individuals. With this information, the NICHD hopes to restore, increase, and maximize the capabilities of people affected by disease and injury. To sponsor training programs for scientists, doctors, and researchers to ensure that NICHD research can continue. By training these professionals in the latest research methods and technologies, the NICHD will be able to conduct its research and make health research progress until all children, adults, families, and populations enjoy good health. The mission of the NICHD is to ensure that every person is born healthy and wanted, that women suffer no harmful effects from reproductive processes, and that all children have the chance to achieve their full potential for healthy and productive lives, free from disease or disability, and to ensure the health, productivity, independence, and well-being of all people through optimal rehabilitation.

Date: February 05, 2025 through to October 05, 2027. All applications are due by 5:00 PM local time of applicant organization.

Budget: Application budgets are limited to \$499,999 direct costs per year and need to reflect the actual needs of the proposed projects. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

[PAR-25-206](#) Pilot Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R01 Clinical Trial Required). NIMH seeks applications for pilot projects to evaluate the preliminary effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions that are matched to the stage of illness in terms of both their focus (e.g., consolidating and maintaining gains from initial treatment, managing residual symptoms/impairment, preventing relapse, promoting adherence and appropriate service use) and intensity/burden. In this pilot phase of effectiveness research, the trial should be designed to evaluate the feasibility, tolerability, acceptability, safety, and potential effectiveness of the approach; to address whether the intervention engages the target(s)/mechanisms(s) presumed to underlie the intervention effects; and to obtain preliminary data needed as a pre-requisite to a larger-scale effectiveness trial (e.g., comparative effectiveness study, practical trial) designed to definitely test the effectiveness of interventions to improve post-acute outcomes.

Date: February 05, 2025 through to October 05, 2027. All applications are due by 5:00 PM local time of applicant organization.

Budget: Direct costs are limited to \$750,000 over the R01 project period, with no more than \$250,000 in direct costs allowed in any single year. The scope of the proposed project should determine the project period. The maximum project period is 3 years.

[PAR-25-207](#) Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R01 Clinical Trial Required). NIMH seeks applications for research projects to evaluate the effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions affecting youth, adults, and older adults. This notice of funding opportunity (NOFO) encourages clinical trials to establish the effectiveness and test hypotheses regarding mechanisms of action, mediators, and predictors and moderators of post-acute phase therapeutic and services interventions that are matched to the stage of illness in terms of both their focus (e.g., consolidating and maintaining gains from initial treatment, managing residual symptoms/impairment, preventing relapse, promoting adherence and appropriate service use) and intensity/burden for promoting optimal longer-term outcomes. This NOFO is intended to support trials that are statistically powered to provide a definitive answer regarding the effectiveness of the post-acute phase intervention. Support for pilot effectiveness trials designed to evaluate the initial feasibility, tolerability, acceptability, safety and preliminary indications of post-acute phase intervention approaches is provided via the R01 NOFO, [PAR-25-206](#)

Date: February 05, 2025 through to October 05, 2027. All applications are due by 5:00 PM local time of applicant organization.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years, however, most awards will be for 3-4 years. Applicants requesting \$500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific Contact at least 8 weeks before submitting the application

[RFA-DA-25-068](#) Targeting Inflammasomes in HIV and Substance Use (R21 Clinical Trial Not Allowed). The goal of this notice of funding opportunity (NOFO) is to encourage research to explore mechanisms of inflammasome activation and their link to neurocognitive disorder (NCD) and immune function in people with HIV and substance use disorders (SUDs). This NOFO supports studies to (1) elucidate the role and the underlying mechanisms of inflammasomes in virus and drug-induced immune activation, (2) identify molecular markers associated with inflammasome pathways in NCD and 3) illuminate the cellular and tissue microenvironments that influence inflammasomes in HIV-1 infection or disease progression among individuals with SUD. Overall goal of this program is to facilitate translation of inflammasome research findings into therapeutic tools that improve clinical outcomes in people with HIV.

Date: March 13, 2025. All applications are due by 5:00 PM local time of applicant organization.

Budget: NIDA intends to support up to four awards for [RFA-DA-25-069](#) and this NOFO (RFA-DA-25-068), corresponding to a total of \$2,000,000 in FY 2026. The combined budget for direct costs for the two-year project period may not exceed \$275,000, and need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 2 years.

[RFA-MH-25-206](#) Bidirectional Influences Between Adolescent Social Media Use and Mental Health (R21 Clinical Trial Optional). Adolescents have increasing access to and spend an increasing amount of time engaging in online social interactions and consuming content on social media platforms, yet there is limited knowledge of how online social behavior and experiences interact with adolescent mental illness and risk for psychopathology. The purpose of this notice of funding opportunity (NOFO) is to encourage applications that focus on understanding bidirectional

relationships between social media use and adolescent mental illness, psychiatric symptoms, and risk or resilience for psychopathology, as well as intervention/services research focused on examining the feasibility, acceptability, and preliminary utility of social-media focused interventions and services. This NOFO seeks shorter, higher-risk R21 grant applications, whereas its companion funding opportunity [RFA-MH-25-205](#) seeks R01 grant applications proposing longer term projects with supporting preliminary data.

Date: January 28, 2025 and October 20, 2025. All applications are due by 5:00 PM local time of applicant organization.

Budget: NIMH intends to commit \$5,000,000 total costs in FY 2025 and FY 2026 to fund 5-6 awards across [RFA-MH-25-205](#) and [RFA-MH-25-206](#), contingent upon NIH appropriations and depending on the number of meritorious applications. The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. **R01:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

[PA-25-172](#) Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional). This notice of funding opportunity (NOFO) encourages applications for research in cancer control and population sciences. The overarching goal is to provide support to promote research efforts on novel scientific ideas that have the potential to substantially advance cancer research in statistical and analytic methods, epidemiology, cancer survivorship, cancer-related behaviors and behavioral interventions, health care delivery, digital health and data science, and implementation science.

Date: February 05, 2025 through to October 05, 2027. All applications are due by 5:00 PM local time of applicant organization.

Budget: The direct costs for any year may not exceed \$250,000 (excluding consortium F&A costs). Within that limit, applications need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

[PA-25-253](#) Exploratory Grants in Cancer Control (R21 Clinical Trial Optional). Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) encourages the submission of exploratory/developmental research grant (R21) applications that focus on different aspects of cancer control by modifying behavior, screening, and understanding etiologic factors contributing to the development of cancer, and developing ways to control cancer. The overarching goal is to provide support to promote the early and conceptual stages of research efforts on novel scientific ideas that have the potential to substantially advance population-based cancer research, such as the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (e.g. epidemiologic, biomedical, behavioral, health care delivery or clinical).

Date: February 16, 2025 through to September 07, 2028. All applications are due by 5:00 PM local time of applicant organization.

Budget: The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in a single year. The maximum project period is 2 years.

[PAR-24-306](#) Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed). Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications for projects to expand, improve, or transform the utility of mammalian cancer and tumor models for translational research. The NCI, through this NOFO, encourages submission of projects devoted to demonstrating that mammalian models, including organoids, tumoroids and cell models, used for translational research are robust representations of human biology, are appropriate to test questions of clinical importance, and provide reliable information for patient benefit. These practical goals contrast with the goals of many mechanistic, NCI-supported R01 projects that use mammals, or develop and use mammalian cancer models, transplantation tumor models, or models derived from mammalian or human tissues or cells for hypothesis-testing, non-clinical research. Among many other possible endeavors, applicants in response to this NOFO could propose demonstrations of how to overcome translational deficiencies of mammalian oncology models, define new uses of mammalian models or their genetics for unexplored translational challenges, advance standard practices for use of translational models, test approaches to validate and credential models, or challenge current practices for how models are used translationally.

Date: February 05, 2025 through to June 05, 2026. All applications are due by 5:00 PM local time of applicant organization.

Budget: Application budgets are limited to \$499,000 direct costs per year. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

[PAR-25-036](#) Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Optional). This Notice of Funding Opportunity (NOFO) invites research grant applications that propose the development and evaluation of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) for molecular targets (e.g., receptors, intracellular messengers, disease-related proteins) that are implicated in brain disorders as tools to study disease pathophysiology and/or for assessing target engagement of potential therapeutic candidates. The objective of this NOFO is to stimulate research in the identification and development of PET and SPECT probes for disorders of primary interest to the NIMH or NIA.

Date: February 05, 2025 through to May 07, 2026. All applications are due by 5:00 PM local time of applicant organization.

Budget: Application budgets are not limited but, need to reflect the actual needs of the proposed project. The total project period may not exceed 5 years. Applicants requesting \$500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific Contact at least 8 weeks before submitting the application.

[PAR-25-049](#) NIH SIREN Neurologic Clinical Trials (UG3/UH3 - Clinical Trial Required). This Notice of Funding Opportunity (NOFO) encourages applications for multi-center clinical trials focused on neurological emergencies. Successful applicants will collaborate and conduct the trial within the NIH SIREN Network. The NIH SIREN Clinical Coordinating Center (CCC) will work with the successful applicants to implement the proposed trial efficiently and the SIREN Data Coordinating Center (DCC) will provide statistical and data management support. The NIH SIREN hubs and their affiliated clinical sites will provide on-site implementation of the clinical protocols. Applicants do not need to be part of the existing SIREN infrastructure to apply under this NOFO. The NIH SIREN Network will also be uniquely poised to collaborate with other U.S. and international consortia necessary to conduct larger, definitive trials of promising interventions for neurological emergencies. Multi-center clinical trials in stroke treatment, recovery, or prevention supported by NINDS will be conducted in the NIH StrokeNet, and not within SIREN.

Date: February 07, 2025 through to February 06, 2026. All applications are due by 5:00 PM local time of applicant organization.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The typical project period is 5 years. The UG3 phase is a maximum of 2 years and UH3 phase a maximum of 5 years. Should a project require more than five years of support, special permission should be requested from NINDS prior to submission of the grant. Applicants requesting \$500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific Contact at least 6 weeks before submitting the application.

Faculty of Medicine and Health Sciences
Research & Internationalisation Development & Support (RIDS) & Grants Management Office (GMO)
009 Kth Floor, Teaching Block, Tygerberg Campus.

Enquiries: fmhsgmo@sun.ac.za

Add “Interest in NIH opportunity” in the subject line.

Add the notice number with hyperlink in the text of the email.